-
Study aim
-
Cardioprotective Effect of Metformin on the level of micro RNAs, mir-222, mir-195, mir-21a, in type 1 diabetes patients
-
Design
-
A randomized controlled clinical trial with a group of 28 patients, enrolled between May 2020 and February 2012, and followed for three months
-
Settings and conduct
-
Patients who are referred to Loghman Hospital Endocrinology Clinic will be informed if they are eligible for inclusion. Initially, the number of patients is twice the sample size. Blood samples are taken and medication begins; patients are contacted weekly and questions about regular drug use and possible side effects. Patients get free visits every month. In case of complications or exclusion criteria, the patient will be excluded. After 3 months of taking the drug, blood samples are taken again.
-
Participants/Inclusion and exclusion criteria
-
Inclusion criteria: age 19 to 45 years; 5 years after onset of diabetes; insulin treatment; patient's blood glucose control for the past three months; HbA1c between 6.5 to 7.5%; no cardiovascular disease; informed consent
Exclusion criteria: pregnancy or pregnancy intent in the near future; renal failure (creatinine greater than or equal to 1.3); history of intraocular injection; history of cardiovascular disease
-
Intervention groups
-
In all patients, plasma levels of the three microRNAs miR-222, miR-195, miR-21a will have measured by PCR, then patients will be treated with metformin at a dose of 500 mg daily for a week. It will reach 2 g daily and then for 12 weeks with adjusted insulin dose and blood glucose monitoring daily, metformin treatment with 2 g daily will continue, then plasma microRNA levels will be measured again
-
Main outcome variables
-
Change in the level of miR-222 after metformin; change in the level of miR-21a after metformin; change in the level of miR-195 after metformin